Topical Treatments:

• Emollients
• Corticosteroids
• Vitamin D analogs
• Calcineurin Inhibitors
• Other Topical Agents

Systemic Treatments:

• Methotrexate
• Oral Retinoids
• Cyclosporine A

Biological Treatments:

• Enbrel (Etanercept)
• Humira (Adalimumab)
• Remicade (Infliximab)
• Stelara (Ustekinumab)

Phototherapy

• PUVA
• UVB
• Excimer Laser & Light

Adalimumab

adalimumab ( Humira ) is approved by the U.S. Food and Drug Administration (FDA) in 2005 for psoriatic arthritis and in 2008 for psoriasis. It blocks tumor necrosis factor-alpha (TNF-alpha), which interrupts the inflammatory cycle of psoriasis and psoriatic arthritis.

The recommended dose of Humira for psoriasis is 80 milligrams (mg) on day 1, and then 40 mg every other week beginning on day 8. The recommended dose for psoriatic arthritis is 40 mg every other week. Humira can be prescribed in combination with topical agents, methotrexate and phototherapy.

It is contraindicated in patients with active serious infections or a history of recurrent infections, patients with a history of heart failure and patients with multiple sclerosis or other types of demyelinating neurologic diseases.  Caution is advised for people who experience any numbness or tingling; have ever had a disease that affects the nervous system; and in the elderly, due to the already increased risk of infection for this age group.